Hoedemaeker RF - Search Results

1

Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and nonprogressors.

van Dekken H, Alers JC, Damen IA, Vissers KJ, Krijtenburg PJ, Hoedemaeker RF, Wildhagen MF, Hop WC, van der Kwast TH, Tanke HJ, Schröder FH. van Dekken H, et al. Among authors: hoedemaeker rf. Lab Invest. 2003 Jun;83(6):789-96. doi: 10.1097/01.lab.0000074889.76221.49. Lab Invest. 2003. PMID: 12808114 Free article.

2

Human prostate-specific transglutaminase: a new prostatic marker with a unique distribution pattern.

Dubbink HJ, Hoedemaeker RF, van der Kwast TH, Schröder FH, Romijn JC. Dubbink HJ, et al. Among authors: hoedemaeker rf. Lab Invest. 1999 Feb;79(2):141-50. Lab Invest. 1999. PMID: 10068203

3

Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.

Hoedemaeker RF, Rietbergen JB, Kranse R, Schröder FH, van der Kwast TH. Hoedemaeker RF, et al. J Urol. 2000 Aug;164(2):411-5. J Urol. 2000. PMID: 10893598 Clinical Trial.

4

Staging prostate cancer.

Hoedemaeker RF, Vis AN, Van Der Kwast TH. Hoedemaeker RF, et al. Microsc Res Tech. 2000 Dec 1;51(5):423-9. doi: 10.1002/1097-0029(20001201)51:5<423::AID-JEMT4>3.0.CO;2-4. Microsc Res Tech. 2000. PMID: 11074612 Review.

5

Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features.

Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WC, van Der Kwast TT, Schröder FH, Tanke HJ, van Dekken H. Alers JC, et al. Among authors: hoedemaeker rf. Am J Pathol. 2001 Feb;158(2):399-406. doi: 10.1016/s0002-9440(10)63983-1. Am J Pathol. 2001. PMID: 11159178 Free PMC article.

6

Defining the window of opportunity in screening for prostate cancer: validation of a predictive tumor classification model.

Vis AN, Hoedemaeker RF, van der Kwast TH, Schröder FH. Vis AN, et al. Among authors: hoedemaeker rf. Prostate. 2001 Feb 1;46(2):154-62. doi: 10.1002/1097-0045(20010201)46:2<154::aid-pros1019>3.0.co;2-1. Prostate. 2001. PMID: 11170143 Clinical Trial.

7

Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).

Vis AN, Hoedemaeker RF, Roobol M, van der Kwast TH, Schröder FH. Vis AN, et al. Among authors: hoedemaeker rf. Prostate. 2001 Jun 1;47(4):252-61. doi: 10.1002/pros.1069. Prostate. 2001. PMID: 11398172 Clinical Trial.

8

The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy.

Hoedemaeker RF, Van der Kwast TH, Schröder FH. Hoedemaeker RF, et al. BJU Int. 2003 Dec;92 Suppl 2:92-6. doi: 10.1111/j.1465-5101.2003.04406.x. BJU Int. 2003. PMID: 14983963 Clinical Trial.

9

Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer.

van der Kwast TH, Ciatto S, Martikainen PM, Hoedemaeker R, Laurila M, Pihl CG, Hugosson J, Neetens I, Nelen V, Di Lollo S, Roobol MJ, Määtänen L, Santonja C, Moss S, Schröder FH. van der Kwast TH, et al. Int J Cancer. 2006 May 15;118(10):2538-42. doi: 10.1002/ijc.21667. Int J Cancer. 2006. PMID: 16353141 Free article. Clinical Trial.

10

Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer.

Hoedemaeker RF, Rietbergen JB, Kranse R, van der Kwast TH, Schröder FH. Hoedemaeker RF, et al. World J Urol. 1997;15(6):339-45. doi: 10.1007/BF01300181. World J Urol. 1997. PMID: 9436283 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42 results

Search Page